Advertisement
CLLS vs TGTX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLLS is a Hold and TGTX is a Buy.
CLLS's RSI Oscillator climbs out of oversold territory
The RSI Indicator for CLLS moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 25 of the 30 cases the stock moved higher. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on CLLS as a result. In 70 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +8.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLLS advanced for three days, in 170 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 48 cases where CLLS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
CLLS broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CLLS entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.624) is normal, around the industry mean (3.498). P/E Ratio (-1.672) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.441) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. CLLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
TGTX in upward trend: price rose above 50-day moving average on October 26, 2026
TGTX moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend. In 32 of 34 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on TGTX as a result. In 65 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for TGTX just turned positive on October 27, 2026. Looking at past instances where TGTX's MACD turned positive, the stock continued to rise in 37 of 44 cases over the following month. The odds of a continued upward trend are 84%.
The 10-day moving average for TGTX crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +3.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where TGTX advanced for three days, in 255 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 183 of 226 cases where TGTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for TGTX moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator moved out of overbought territory. In 35 of the 48 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TGTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
TGTX broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. TGTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 43 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.159) is normal, around the industry mean (3.498). P/E Ratio (19.551) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (11.136) is also within normal values, averaging (440.869).
CLLS | TGTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 28 | 41 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 61 Fair valued | 89 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 43 | |
SMR RATING 1..100 | 98 | 14 | |
PRICE GROWTH RATING 1..100 | 65 | 35 | |
P/E GROWTH RATING 1..100 | 8 | 7 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CLLS's Valuation (61) in the Biotechnology industry is in the same range as TGTX (89). This means that CLLS’s stock grew similarly to TGTX’s over the last 12 months.
TGTX's Profit vs Risk Rating (43) in the Biotechnology industry is somewhat better than the same rating for CLLS (100). This means that TGTX’s stock grew somewhat faster than CLLS’s over the last 12 months.
TGTX's SMR Rating (14) in the Biotechnology industry is significantly better than the same rating for CLLS (98). This means that TGTX’s stock grew significantly faster than CLLS’s over the last 12 months.
TGTX's Price Growth Rating (35) in the Biotechnology industry is in the same range as CLLS (65). This means that TGTX’s stock grew similarly to CLLS’s over the last 12 months.
TGTX's P/E Growth Rating (7) in the Biotechnology industry is in the same range as CLLS (8). This means that TGTX’s stock grew similarly to CLLS’s over the last 12 months.
| CLLS | TGTX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 83% | 2 days ago 73% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 80% | 2 days ago 81% |
| MACD ODDS (%) | N/A | 2 days ago 84% |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 74% | 2 days ago 82% |
| Advances ODDS (%) | 6 days ago 79% | 4 days ago 83% |
| Declines ODDS (%) | 2 days ago 89% | 2 days ago 83% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 81% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLLS’s FA Score shows that 1 FA rating(s) are green while TGTX’s FA Score has 2 green FA rating(s).
- CLLS’s FA Score: 1 green, 4 red.
- TGTX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLLS’s TA Score shows that 3 TA indicator(s) are bullish while TGTX’s TA Score has 6 bullish TA indicator(s).
- CLLS’s TA Score: 3 bullish, 4 bearish.
- TGTX’s TA Score: 6 bullish, 4 bearish.
Price Growth
CLLS (@Biotechnology) experienced а +10.28% price change this week, while TGTX (@Biotechnology) price change was +7.83% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.
Reported Earning Dates
CLLS is expected to report earnings on Mar 04, 2027.
TGTX is expected to report earnings on Mar 02, 2027.
Industries' Descriptions
@Biotechnology (-3.38% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CLLS and
Correlation & Price change
A.I.dvisor indicates that over the last year, CLLS has been loosely correlated with SLN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CLLS jumps, then SLN could also see price increases.
| Ticker / NAME | Correlation To CLLS | 1D Price Change % | ||
|---|---|---|---|---|
| CLLS | 100% | -11.28% | ||
| SLN - CLLS | 43% Loosely correlated | +0.15% | ||
| MDGL - CLLS | 40% Loosely correlated | +0.51% | ||
| PMVP - CLLS | 38% Loosely correlated | +4.96% | ||
| AXON - CLLS | 36% Loosely correlated | +2.71% | ||
| TGTX - CLLS | 36% Loosely correlated | -0.08% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| XLC | 108.69 | 1.13 | +1.05% |
| State Street Communication Services Select Sector SPDR ETF (XLC) | |||
| KPDD | 4.86 | N/A | N/A |
| KraneShares 2x Long PDD Daily ETF (KPDD) | |||
| HYBI | 47.52 | -0.02 | -0.04% |
| NEOS Enhanced Income Credit Select ETF (HYBI) | |||
| FFEM | 38.15 | -0.04 | -0.10% |
| Fidelity Fundamental Emerging Markets ETF | |||
| PRIV | 24.10 | -0.07 | -0.27% |
| SPDR SSGA Apollo IG Public & Private Credit ETF | |||